Corrigendum to “Synthesis and clinical application of new drugs approved by NMPA in 2023” [European Journal of Medicinal chemistry 283 (2025) 117181/EJMECH-d-24-03758]

IF 5.9 2区医学 Q1 CHEMISTRY, MEDICINAL

European Journal of Medicinal Chemistry Pub Date : 2025-06-11 DOI:10.1016/j.ejmech.2025.117853

Lijuan Xie , Yingying Wang , Kunyu Wang , Wanying Chen , Fuwei Yang

引用次数: 0

查看原文本刊更多论文

“2023年NMPA批准新药的合成和临床应用”的勘误表[欧洲药物化学杂志283 (2025)117181/EJMECH-d-24-03758]

作者感到遗憾<；插入勘误文本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Medicinal Chemistry 化学-医药化学

CiteScore

11.70

自引率

9.00%

发文量

863

审稿时长

29 days

期刊介绍： The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.